Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Colonization pressure as a risk factor for colonization by multiresistant Acinetobacter spp and carbapenem-resistant Pseudomonas aeruginosa in an intensive care unit.

DalBen MF, Basso M, Garcia CP, Costa SF, Toscano CM, Jarvis WR, Lobo RD, Oliveira MS, Levin AS.

Clinics (Sao Paulo). 2013;68(8):1128-33. doi: 10.6061/clinics/2013(08)11. Erratum in: Clinics (Sao Paulo). 2013 Dec;68(12):1559.

2.

Ceftriaxone and ciprofloxacin restriction in an intensive care unit: less incidence of Acinetobacter spp. and improved susceptibility of Pseudomonas aeruginosa.

Medina Presentado JC, Paciel López D, Berro Castiglioni M, Gerez J.

Rev Panam Salud Publica. 2011 Dec;30(6):603-9.

3.

Outbreak of resistant Acinetobacter baumannii- measures and proposal for prevention and control.

Romanelli RM, Jesus LA, Clemente WT, Lima SS, Rezende EM, Coutinho RL, Moreira RL, Neves FA, Brás Nde J.

Braz J Infect Dis. 2009 Oct;13(5):341-7. doi: 10.1590/S1413-86702009000500005.

4.

Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.

Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J.

Antimicrob Agents Chemother. 2007 Jun;51(6):1967-71. Epub 2007 Apr 9.

5.

Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients.

Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M.

Ann Clin Microbiol Antimicrob. 2014 Jan 9;13:7. doi: 10.1186/1476-0711-13-7.

6.

Nosocomial urinary tract infections caused by Pseudomonas aeruginosa and Acinetobacter species: sensitivity to antibiotics and risk factors.

Djordjevic Z, Folic MM, Zivic Z, Markovic V, Jankovic SM.

Am J Infect Control. 2013 Dec;41(12):1182-7. doi: 10.1016/j.ajic.2013.02.018. Epub 2013 May 29.

PMID:
23726656
7.

"Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa.

Marchaim D, Perez F, Lee J, Bheemreddy S, Hujer AM, Rudin S, Hayakawa K, Lephart PR, Blunden C, Shango M, Campbell ML, Varkey J, Manickam P, Patel D, Pogue JM, Chopra T, Martin ET, Dhar S, Bonomo RA, Kaye KS.

Am J Infect Control. 2012 Nov;40(9):830-5. doi: 10.1016/j.ajic.2011.10.013. Epub 2012 Feb 10.

8.

Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.

Mohanty S, Maurya V, Gaind R, Deb M.

J Infect Dev Ctries. 2013 Nov 15;7(11):880-7. doi: 10.3855/jidc.2924.

9.

Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children.

Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M.

Pediatr Infect Dis J. 2013 Apr;32(4):e151-4. doi: 10.1097/INF.0b013e3182804b49.

PMID:
23249908
10.

Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.

Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN.

Int J Antimicrob Agents. 2005 Jan;25(1):57-61.

PMID:
15620827
11.

Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.

Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS.

J Antimicrob Chemother. 2008 Jun;61(6):1369-75. doi: 10.1093/jac/dkn128. Epub 2008 Mar 25.

12.
13.

How carbapenem-resistant Acinetobacter spp. established in a newly constructed hospital.

Lu PL, Huang LY, Lian ST, Chang K, Lin CL, Hwang IJ, Chiang WG, Chen YH, Lin SF, Siu LK.

Int J Antimicrob Agents. 2008 May;31(5):463-6. doi: 10.1016/j.ijantimicag.2008.01.019. Epub 2008 Mar 24.

PMID:
18359613
14.

Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F.

J Clin Microbiol. 2000 Nov;38(11):4086-95.

15.

Reduction in the prevalence of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in New York City.

Abdallah M, Olafisoye O, Cortes C, Urban C, Charles C, Landman D, Quale J.

Am J Infect Control. 2015 Jun;43(6):650-2. doi: 10.1016/j.ajic.2015.02.018. Epub 2015 Mar 26.

PMID:
25818022
16.

Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009.

Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y; KONSAR Group.

Yonsei Med J. 2011 Sep;52(5):793-802. doi: 10.3349/ymj.2011.52.5.793.

17.

Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study.

Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros EA.

Infect Control Hosp Epidemiol. 2006 Nov;27(11):1270-3. Epub 2006 Oct 20.

PMID:
17080392
18.

Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital.

Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP.

Pharmacotherapy. 1999 Sep;19(9):1080-5.

PMID:
10610015
19.

[Infections caused by Acinetobacter spp. in critically ill ICU patients].

Alvarez-Lerma F, Palomar M, Insausti J, Olaechea P, Cerdá E, Castillo F, Martínez-Pellús A; Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UCI.

Enferm Infecc Microbiol Clin. 2005 Nov;23(9):533-9. Spanish.

PMID:
16324565
20.

Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit.

Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, Lim JE, Lee SK, Lee SH, Lee KJ, Kang YA, Kim SK, Chang J, Kim YS.

BMC Infect Dis. 2010 Jul 30;10:228. doi: 10.1186/1471-2334-10-228.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk